Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
List view / Grid view
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
The use of high-density MEAs to probe single cell and network activity electrophysiology of a hiPSC-derived Huntington’s disease model
Download this infographic to find out why the method of generating human iPSC-derived cells matters.
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.